secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024677
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma Q2 FY2023: net loss $4.9M; cash $34.9M; advances three clinical programs
--------------------------------------------------------------------------------

- Net loss $4.9M ($0.11/sh) vs net income $1.0M in prior-year quarter; operating loss $5.1M.
- R&D expenses rose to $3.3M from $0.6M due to PK studies for GTX-104, -102, -101.
- Cash & short-term investments $34.9M as of Sep 30, 2022, down from $43.7M at Mar 31, 2022; runway through at least Mar 2024.
- FDA Type C meeting on GTX-104 Phase 3 design expected by end of 2022/early Q1 2023; GTX-102 and GTX-101 PK topline results by end of 2022.
- Vimal Kavuru appointed Chairman of the Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017022024677/0000950170-22-024677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017022024677/acst-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer